DGAP-News: Neovacs S.A. / Key word(s): Miscellaneous Neovacs S.A.: Stellar Biotechnologies and Neovacs S.A. Expand KLH Supply Relationship 01.04.2015 / 08:00 --------------------------------------------------------------------- Stellar Biotechnologies and Neovacs S.A. Expand KLH Supply Relationship Companies Sign KLH Supply Agreement for Neovacs' Kinoid Clinical Trials and Initial Commercialization PORT HUENEME, CA and PARIS, FRANCE, (April 1st, 2015) -- Stellar Biotechnologies, Inc. ("Stellar" or the "Company") (OTCQB: SBOTF) (TSX-V: KLH) and Neovacs S.A., ("Neovacs") (Alternext Paris: ALNEV) today announced that the Companies have entered into an expanded supply agreement to meet Neovacs' requirements for Keyhole Limpet Hemocyanin (KLH), a primary component of Neovacs' proprietary Kinoid immunotherapy technology. The new agreement extends and expands the supply contracts previously in place between the Companies, in order to ensure the continued supply of Stellar KLH(TM) to Neovacs during its Kinoid clinical trials and to support the expected commercial roll-out of Neovacs' lead product candidate IFNα-Kinoid, an immunotherapy being developed for the treatment of systemic lupus erythematosus ("lupus"). Stellar is a leader in the sustainable manufacture of KLH, an immune-stimulating protein widely used as a carrier molecule in immunotherapies under development for a variety of disease indications. Immunotherapy uses a patient's own immune system to target and treat diseases. KLH can only be produced from a scarce marine source. Stellar believes it is the only company with the proprietary technology to manage sustainable, scalable production of GMP quality KLH to meet future pharmaceutical industry demands. Neovacs is a leader in the development of active immunotherapies for the treatment of chronic autoimmune diseases. Neovacs' patented Kinoid technology combines a select cytokine of interest attached to KLH as the immune-stimulating carrier protein. The resulting immunotherapy uses the patient's immune system to generate antibodies against the targeted disease. Neovacs' lead product candidate, IFN(-Kinoid, has successfully completed a Phase I/IIa clinical trial for lupus. The Company's Scientific Advisory Board (SAB) members have announced their full support for the planned Phase IIb trial of IFNα-Kinoid in approximately 160 patients in Europe, Latin America and Asia. This Phase IIb study is expected to begin mid-2015. A U.S. Phase IIa trial of IFNα-Kinoid for the treatment of lupus in the U.S. is expected to commence by early 2016. "We have enjoyed a long-standing and successful relationship with Stellar Biotechnologies as our key KLH supplier," said Miguel Sieler, Chief Executive Officer of Neovacs. "This new agreement with Stellar comes at a pivotal point for Neovacs, as we are preparing to launch multicenter clinical trials with IFNα-Kinoid and are strengthening our U.S. operations through the recent formation of a wholly-owned subsidiary, Neovacs, Inc. The new supply agreement will ensure that Neovacs has access to a scalable, stable supply of GMP grade KLH as our Kinoid products advance through clinical development and we prepare for the expected commercial launch." "Expanding our supply commitment to Neovacs to include late-stage clinical trials and expected initial commercialization is an excellent demonstration of the growing commercial prospects for our core KLH business," said Frank Oakes, President and CEO of Stellar Biotechnologies. "We also see this is as positive validation for the use of Stellar KLH(TM) in the development of new immunotherapy treatments." Under the terms of the agreement, Neovacs will purchase Stellar KLH(TM) for use in its proprietary KLH-based Kinoid immunotherapies in the European Union, Latin America, Asia, the U.S. and Canada. Neovacs will use Stellar KLH(TM) for its planned Phase II and Phase III clinical trials and for expected commercial manufacturing of its products for up to one year following market approval. Neovacs will manage and fund all product development and regulatory submissions for its immunotherapy products and act as the sponsor company for the future clinical trials. Stellar will supply GMP grade KLH to Neovacs according to agreed specifications, quantities, and pricing, as well as maintain a master file with the U.S. FDA for the KLH product. Stellar will also provide professional, technical, and regulatory support to Neovacs. The agreement has an initial five-year term, which may be renewed by Neovacs in one-year increments. About Neovacs Neovacs (Alternext Paris: ALNEV) is a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNα-Kinoid, an immunotherapy being developed for the indication of lupus. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. For more information on Neovacs, visit www.neovacs.fr About Stellar Biotechnologies, Inc. Stellar Biotechnologies, Inc. (OTCQB: SBOTF) (TSX-V: KLH) is a leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, immune disorders, Alzheimer's, and inflammatory diseases) as well as a finished product for measuring immune status. Stellar Biotechnologies is unique in its proprietary methods, facilities, and KLH technology. It is committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies. Visit www.stellarbiotech.com and the Stellar KLH knowledge base www.klhsite.org. Stellar Biotechnologies Company Contact: Mark A. McPartland Vice President of Corporate Development and Communications +1 (805) 488-2800 ext. 103 markmcp@stellarbiotech.com www.stellarbiotech.com Neovacs Company Contacts: NEOVACS - Investor Relations Nathalie Trépo +33 (0)1 53 10 93 00 ntrepo@neovacs.com Investor Relations / Financial Communications - NewCap Valentine Brouchot / Pierre Laurent +33 (0)1 44 71 94 94 theradiag@newcap.fr Investor Relations / Financial Communications Germany - MC Services Raimund Gabriel +49-89-210228-30 raimund.gabriel@mc-services.eu Press / U.S. Inquiries - The Ruth Group Melanie Sollid-Penton 1.646.536.7023 msollid@theruthgroup.com Forward Looking Statements This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "will," "would," "could," "should," "might," "potential," or "continue" and variations or similar expressions. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include, but may not be limited to: general economic and business conditions; technology changes; competition; changes in strategy or development plans; governmental regulations and the ability or failure to comply with governmental regulations; the timing of anticipated results; and other factors referenced in the Company's filings with securities regulators. For a discussion of further risks and uncertainties related to the Company's business, please refer to the Company's public company reports filed with the TSX Venture Exchange and the U.S. Securities and Exchange Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such statements. This press release does not constitute an offer or solicitation of an offer for sale of any securities in any jurisdiction, including the United States. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the information contained in this press release. --------------------------------------------------------------------- 01.04.2015 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: Neovacs S.A. 3-5, Impasse Reille 75014 Paris France Phone: +33 (0)1 53 10 93 00 Fax: +33 (0)1 53 10 93 03 E-mail: www.neovacs.fr Internet: info@neovacs.fr ISIN: FR0004032746 WKN: A1CVKR Listed: Regulated Unofficial Market in Stuttgart; Open Market in Frankfurt End of News DGAP News-Service --------------------------------------------------------------------- 339839 01.04.2015
DGAP-News: Neovacs S.A.: Stellar Biotechnologies and
Top 10 Most Recent News Articles
TNBC Advocate Campaign Targets Gaps in Patient Clarity
Triple-negative is a heavy phrase to hand somebody without a map. Tigerlily Foundation and the Breast Cancer Resource Center are trying to close that gap with a national education campaign scheduled to launch publicly on January 11, 2027. The plan is straightforward on paper: train and mobilize 100 patient advocates across the country to explain triple-negative breast...
Continue Reading
UTI Faces Fresh Scrutiny After Its Earnings Guidance Miss
A Guidance Gap That Cannot Be Shrugged Off A $0.20-per-share hole is a nasty thing to find after management said it could see the road ahead. Universal Technical Institute reported fiscal 2026 diluted earnings per share of $0.60, below the $0.71 to $0.80 range it reaffirmed on May 6. That is at least $0.11 under the low end and roughly 21% below the midpoint. For...
Continue Reading
Why Brief Chiropractic Visits Still Need Clear Expectations
A few minutes on the table can sound almost suspiciously brisk when somebody is dealing with a stiff neck, sore back, or nagging joint discomfort. Yet that is the central point in Dr. Craig Peterson's explanation for HelloNation: the adjustment itself may be brief, while the value of a chiropractor visit depends on a focused assessment, appropriate technique, and whether...
Continue Reading
PBS Holiday Special Bets on Apollo 8, Music and Unity
A moon mission, a 360-voice choir, and Christmas television make an unusual bundle, but that is precisely why this year’s Tabernacle Choir special has some real staying power. Peace on Earth: Christmas with The Tabernacle Choir is not trying to chase whatever noisy trend is chewing up attention this week. It is building a 90-minute holiday event around Apollo 8,...
Continue Reading
North Richland Hills Bets on Its Visitor Momentum Now
A crowded family attraction map is a nice problem for a Texas city to have, and North Richland Hills is trying to turn that pile of assets into a cleaner regional tourism machine. On Nov. 20, 2026, the city introduced “The Place You Never Outgrow,” its first destination-marketing campaign, built with Flat Five Marketing. This is not a stock story in the usual...
Continue Reading
Straub's Court Win Raises Cost of Seven-Year Fight
Seven years of courtroom smoke over an under-$80,000 lien is the sort of mess that makes any business owner grind his teeth. Palm Beach Polo says its president, Glenn Straub, has again prevailed against Jessica Nicodemo in Palm Beach County, following an earlier Broward County dismissal of related claims. The company also says Vice President Sal Spano received a directed...
Continue Reading
Bill Targets 15% Federal Goal for Women-Owned Firms
Federal procurement has a stubborn habit of sounding abstract until you remember that contracts can decide whether a small company hires, invests, or simply keeps the lights on. Senator Adam Schiff introduced the Women's Economic Fairness and Small Business Contracting Act on November 19, 2026, proposing to raise the federal goal for Women-Owned Small Businesses from 5%...
Continue Reading
Green Lumber Recall Raises a Serious Safety Question
A blister-pack code is doing far more work than it ever should. Green Lumber Holdings is recalling Green Lumber Natural Fuel For Men, lot GL01 with expiration 09/27, after FDA laboratory analysis confirmed undeclared tadalafil in additional samples. The company says the consumer-level recall begins November 19, 2026. This is not a cute labeling nitpick or a marketing...
Continue Reading
RBI Heads to Morgan Stanley With Plenty to Explain
Two executives, one New York stage, and a short calendar gap give Restaurant Brands International a clean chance to address investors without the usual blizzard of quarterly slides. Chief Executive Officer Josh Kobza and Chief Financial Officer Sami Siddiqui are scheduled for a fireside chat at Morgan Stanley's Global Consumer & Retail Conference on December 2, 2026, at...
Continue Reading
IT Tech Packaging's Going-Concern Warning Lands Hard
A paper maker can survive plenty of ugly quarters; it cannot casually shrug off an auditor questioning whether it can keep operating. That is the cold part of IT Tech Packaging's Nov. 19 disclosure. Its newly filed Form 10-K for the year ended Dec. 31, 2025 carries a “Material Uncertainty Related to Going Concern” paragraph from Audit Alliance LLP. Nobody should dress...
Continue ReadingTop 5 Most Recently Viewed Articles
InfoSync Services Partners with CogentHub for Strategic Growth
InfoSync Services Partners with CogentHub for Strategic Growth In a significant move for the professional services landscape, InfoSync Services, a renowned provider of outsourced solutions, has been sold from Staple Street Capital to CogentHub. This transition marks an exciting chapter not only for InfoSync but also for its clients and the wider market. Understanding...
Continue Reading
Call for Major Economic Stimulus in China: $1.4 Trillion Boost
China's Proposal for Economic Stimulus Amid global economic strains, a well-regarded former central bank adviser has put forth a notable idea: China could consider issuing ultra-long-term treasury bonds, which might generate an impressive 10 trillion yuan (around $1.4 trillion) in stimulus. This proactive suggestion was shared at the China Macroeconomy Forum and...
Continue Reading
Cavitation Technologies: Strategic Growth Plans Ahead of 2025
Strategic Growth Plans for Cavitation Technologies, Inc. Cavitation Technologies, Inc. (OTCQB: CVAT) is committed to advancing its innovative capabilities in the fields of water treatment and beverage technology. As the company looks toward the future, it aims to capitalize on existing technologies while exploring new partnerships that will enhance its operations....
Continue Reading
How a $1000 Investment in Insulet Transformed Over 15 Years
How Insulet Has Thrived Over the Years Insulet (NASDAQ:PODD) has shown remarkable performance, exceeding market expectations over a 15-year span with an impressive annualized return of 23.78%. This is a testament to strong financial growth, significantly outperforming many competitors. The Incredible Growth of a $1000 Investment Consider this: imagine if you invested...
Continue Reading
Synovus Executives Set to Discuss Insights at Conference
Synovus Financial Corp. at the BancAnalysts Association Conference Synovus Financial Corp. (NYSE: SNV) is preparing for its participation in a highly anticipated conference that gathers financial experts and analysts. The event will feature a fireside chat with the company’s leadership, including Chairman, CEO, and President Kevin Blair along with Executive Vice...
Continue Reading